Table 1 Patient characteristics

Gender, n (%)

 Female

16 (35.6)

23 (51.1)

39 (43.3)

0.202

 Male

29 (64.4)

22 (48.9)

51 (56.7)

 Age, (years) median (IQR)

66 (58 - 73)

70 (60 - 73)

69 (59 -73)

0.678

 BMI, (kg/m2) median (IQR)

25 (22 - 27)

24 (21 - 27)

24 (21 - 27)

0.190

Tumor location, n (%)

 Pancreatic head

38 (84.4)

31 (68.9)

69 (76.7)

0.235

 Pancreatic body

6 (13.4)

12 (26.7)

18 (20)

 Pancreatic tail

1 (2.2)

2 (4.4)

3 (3.3)

 NACHT, n (%)

16 (35.6)

27 (62.8)

43 (47.8)

0.034

Regimen

 Folfirinox

12 (75)

21 (77.8)

33 (76.7)

0.870

 Gemcitabine based

2 (12.5)

4 (14.8)

6 (14)

 Other

2 (12.5)

2 (7.4)

4 (9.3)

 Nr cycles, median (IQR)

5 (4 - 8)

6 (4 – 8)

5 (4-8)

0.476

CA 19-9, (kU/L) median (IQR)

 Upfront surgery

249 (22 – 6710)

52 (23 – 255)

193 (23 – 873)

0.264

 Pre-NACHT

85 (26 – 232)

190 (85 - 543)

141 (52 – 520)

0.138

 Post-NACHT

40 (4 – 91)

41 (16 – 158)

41 (13 -120)

0.472

RECIST, n (%)

 Partial response

11 (68.8)

20 (74.1)

31 (72.1)

0.737

 Stable disease

5 (31.2)

7 (25.9)

12 (27.9)

Surgical Procedure, n (%)

 Duodenopancreatectomy

26 (57.8)

17 (37.8)

43 (47.8)

0.023

 Left pancreatectomy

2 (4.4)

3 (6.7)

5 (5.6)

 Total pancreatectomy

3 (6.7)

0 (0)

3 (3.3)

 Exploration/derivation

14 (31.1)

25 (55.5)

39 (43.3)

 Venous resection, n (%)

10 (23)

2 (5)

12 (15)

0.029

 Wedge resection

2 (20)

1 (50)

3 (25)

0.455

 Segment resection

8 (80)

1 (50)

9 (75)

Resectability, n (%)

 R0

6 (13.6)

5 (11.1)

11 (12.4)

0.075

 R1

24 (54.5)

14 (31.1)

38 (42.4)

 R2

1 (2.3)

1 (2.2)

2 (2.2)

 Unresectable

14 (29.5)

25 (55.6)

39 (43)

 Vascular infiltration

10 (76)

21 (88)

31 (85)

0.249

 Liver metastases

1 (8)

3 (12)

4 (10)

 Peritoneal metastases

2 (16)

0 (0)

2 (5)

Clavien-Dindo, n (%)

 Minor complication (Grade I-II)

12 (26.7)

18 (40)

30 (33.3)

0.263

 Major complication (Grade III-IV)

2 (4.4)

5 (11.1)

7 (7.8)

0.434

 90-day mortality, n (%)

3 (6.7)

0 (0)

3 (3.3)

0.242